Approval · Notice of Compliance 16248 · 2014
VAN-BICALUTAMIDE: Notice of Compliance 16248
Issued November 3, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16248
- Date
- November 3, 2014
- Company
- Vanc Pharmaceuticals IncRichmond, British Columbia, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Therapeutic class
- Non-steroidal antiandrogen
- Canadian reference product
- CASODEX (Astrazeneca Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VAN-BICALUTAMIDE | 02428709 | Cancelled Post Market |
Medicinal ingredients
- BICALUTAMIDE 50 MG per TAB